Managing B-Cell Lymphomas in the Second-Line Setting: The Role of CAR T-Cell Therapy

Project Oncology®

Host: Jennifer Caudle, DO
Guest: Sarah Rutherford, MD
Due to its strong response rates and manageable adverse events, CAR T-cell therapy is now considered the standard-of-care treatment for B-cell lymphomas in the second-line setting, which could lead to better outcomes for patients. Learn more about the efficacy and safety profile of CAR T-cell therapy with Dr. Jennifer Caudle and Dr. Sarah Rutherford, Assistant Professor of Medicine in the Division of Hematology-Oncology at Weill Cornell Medicine.